Wells Fargo & Company MN boosted its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 32.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,558,531 shares of the biopharmaceutical company’s stock after buying an additional 383,713 shares during the quarter. Wells Fargo & Company MN owned approximately 0.70% of Alexion Pharmaceuticals worth $218,647,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ALXN. Fiduciary Trust Co. acquired a new stake in shares of Alexion Pharmaceuticals in the second quarter valued at about $111,000. Dupont Capital Management Corp acquired a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at about $156,000. BT Investment Management Ltd acquired a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at about $165,000. Penserra Capital Management LLC grew its position in shares of Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 144 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in shares of Alexion Pharmaceuticals in the second quarter valued at about $160,000. Institutional investors own 94.15% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $109.81 on Friday. The stock has a market cap of $24,150.58, a P/E ratio of 22.11, a PEG ratio of 1.18 and a beta of 1.22. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.12. The business had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.23 EPS. sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current fiscal year.

A number of research firms recently weighed in on ALXN. TheStreet lowered shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Royal Bank Of Canada boosted their price target on shares of Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Stifel Nicolaus lowered their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $170.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $155.06.

In related news, EVP Julie O’neill sold 4,375 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total value of $636,300.00. Following the completion of the transaction, the executive vice president now owns 26,092 shares in the company, valued at $3,794,820.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The disclosure for this sale can be found here. Insiders sold a total of 5,330 shares of company stock worth $774,851 over the last three months. Insiders own 4.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Wells Fargo & Company MN Has $218.65 Million Position in Alexion Pharmaceuticals, Inc. (ALXN)” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/01/wells-fargo-company-mn-has-218-65-million-position-in-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.